Apr 08, 2020
Mimeo Supports Intercept Pharmaceuticals Continued Training Amidst Pandemic
Jan 24, 2020
Non-Alcoholic Steatohepatitis (NASH) H1, 2020: Pipeline Landscape; Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Aug 29, 2019
Global $61.6 Bn Non-Alcoholic Steatohepatitis (NASH) Drugs Market to 2028
Jul 10, 2019
The global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period
Feb 04, 2019
Global Non-Alcoholic Steatohepatitis (NASH) Market 2018-2026: Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis
Nov 27, 2018
Nonalcoholic Steatohepatitis (NASH) Market Analysis, Market size, Epidemiology, Leading companies and Competitive Analysis by DelveInsight
Apr 30, 2018
Non Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Drug Development Pipeline Review 2018: 195 Pipeline Products in development for NASH and 65 Products in Development for NAFLD
Dec 08, 2017
Nonalcoholic Steatohepatitis (NASH) Market Report to 2027
Oct 10, 2017
Non-Alcoholic Steatohepatitis Drugs Market (NASH) Trends, Size, Growth, Opportunities and 2026 Forecast Report
Oct 10, 2017
Metacrine's FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.
Sep 12, 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT